Peer-influenced content. Sources you trust. No registration required. This is HCN.
JAMA Network
The 18-month OS rates in this trial were: 66.7% for neoadjuvant mFOLFIRINOX 47.3% for neoadjuvant mFOLFIRINOX and hypofractionated radiotherapy 87.5% for mFOLFIRINOX followed by pancreatectomy 78.9% for mFOLFIRINOX plus radiotherapy followed by pancreatectomy The authors state these results “suggest that mFOLFIRINOX represents a reference neoadjuvant treatment regimen for borderline resectable pancreatic cancer; however, the role of radiotherapy in this setting remains undefined.”
Oncology, Medical July 25th 2022
MedPage Today
This paring of PARP inhibitor and immune checkpoint inhibitor may be a viable non-cytotoxic maintenance therapy option for patients with platinum-sensitive pancreatic ductal adenocarcinoma. At a median follow-up of 23.0 months, combining the PARP inhibitor niraparib with the anti CTLA-4 antibody ipilimumab achieved a 6-month PFS rate of 59.6%, which was superior to the comparator — a clinically meaningful benchmark of 44%. The results were not the same when a PD-1 inhibitor (nivolumab) were used. That trial arm yielded a poorer 6-month PFS vs the benchmark.
BroadcastMed
This is a 1.75-hour credit expert round-table featuring members of UPMC faculty. The group dialogue together on the state-of the art in pancreatic cancer and their experience in biliary stenting including advantages of metal versus plastic stenting, and their experience in recent advances in molecular testing of pancreatic cysts, identifying those patients that will benefit from targeted surveillance of pancreatic cancer, and methods of performing PDAC surveillance and their outcomes. They also discuss prevention and management of post-op complications, and pain control in this population.
Oncology, Medical May 31st 2022
Radiopaedia
This Radiopedia entry updated in April provides a concise summary of clinical and radiographic features of pNETs and an outline of classification and treatment. In addition to the summary information, there are a score of CT and PET CT studies to explore.
Northwestern Medicine
When tested in mice with pancreatic cancer, a BET inhibitor/anti-PD-1 combination prevented neoplastic transformation induced by the oncogene KRAS, increased survival and increased the recruitment of cytotoxic T-cells to the tumor.
Oncology, Medical May 10th 2022
Journal of Clinical Oncology
Initial results of the PREOPANC trial — comparing the addition of neoadjuvant chemoradiation therapy of gemcitabine combined plus Gy radiotherapy to standard care — failed to demonstrate a statistically significant overall survival (OS) improvement versus standard care of upfront surgery followed by adjuvant therapy. The long-term results, however, demonstrate significant benefit with neoadjuvant chemoradiation therapy consisted of gemcitabine combined plus Gy radiotherapy. The five year OS rate was 20.5% (95% CI, 14.2 to 29.8) with neoadjuvant chemoradiotherapy and 6.5% with upfront surgery.
Hematology/Oncology February 8th 2022